AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00487669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex, pemetrexed
Description: The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
Study NCT02569073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol 5 mg, every other night, orally
Study NCT02569073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo--no drug
Study NCT01433666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast (EU: Daxas, USA: Daliresp)
Description: Acute intervention: 1 time each dose on different days. Capsulated
Study NCT01433666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute intervention: single administration, capsulated form.
Study NCT01433666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: roflumilast
Description: Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
Study NCT03552406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous Infusion for 1 hour (2 hours at initial dose)
Study NCT01946867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBTXR3 activated by IMRT
Study NCT00989300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - rabeprazole
Description: 20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
Study NCT00989300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - omeprazole
Description: 20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
Study NCT00989300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment C - placebo
Description: placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
Study NCT01433666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast
Description: Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
Study NCT02437292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression with stretching
Study NCT00415467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GliaSite Radiation Therapy System
Description: Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
Study NCT02433717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
Study NCT01777646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Study NCT01946945 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing after Blastocyst biopsy
Description: PGD using blastocyst biopsy and testing of the biopsy by NGS
Study NCT00482833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28).
Study NCT01301573 — intervention group
Intervention type: BIOLOGICAL
Intervention: rAAV-GAD
Study NCT00482833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1.
Study NCT00482833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
Study NCT00482833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
Study NCT00482833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: all-trans retinoic acid
Description: Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed.
Study NCT00482833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Description: Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26).
Study NCT04491058 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SSCT thickness measurement
Description: Thickness measurement with ultrasound
Study NCT01352039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin Sodium - Eurofarma
Description: Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
Study NCT01352039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium - APP Pharmaceuticals
Description: Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
Study NCT00858286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry, PEF measurements and diary cards to evaluate control of Asthma
Description: No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
Study NCT01743547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
Study NCT00851591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenugreek
Description: 3 capsules 3 times per day with a full glass of water each dose for 7 days
Study NCT00851591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Psyllium)
Description: 3 capsules 3 times a day with a full glass of water each dose for 7 days
Study NCT03655431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
Study NCT03655431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
Study NCT01202448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF analysis
Description: The cerebrospinal fluid will be evaluated via lumbar puncture.
Study NCT01727271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Study NCT01727271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Study NCT01727271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b
Study NCT00360360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
Study NCT00360360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC 6.0 IV Day 1
Study NCT00360360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15mg/kg IV infusion,Day 1
Study NCT00360360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib 150 mg by mouth daily
Study NCT01318499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
Study NCT01318499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension, 0.1%
Description: Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
Study NCT01318499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Vehicle 0.3%
Description: Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
Study NCT03693430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
Study NCT03693430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
Study NCT01066806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling on increasing calcium intake
Description: The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
Study NCT01066806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observation
Description: observe normal dairy intake
Study NCT03039478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol 7g
Description: Xylitol 7g in 300mL tap water
Study NCT02042716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnosis of white matter damage in preterm infants
Description: Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
Study NCT01536067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Given IV
Study NCT00455351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Increasing dosing, phase I
Study NCT00849459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-mediated human interleukin-12
Description: The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC.
Study NCT00945165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: various exercise characteristics
Study NCT00945165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise
Description: No exercise control period
Study NCT03039478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol 10g
Description: Erythritol 10g in 300mL tap water
Study NCT03039478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol 17g
Description: Xylitol 17g in 300mL tap water
Study NCT03039478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol 35g
Description: Xylitol 35g in 300mL tap water
Study NCT03039478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol 25g
Description: Erythritol 25g in 300mL tap water
Study NCT03039478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol 50g
Description: Erythritol 50g in 300mL tap water
Study NCT01536067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC
Study NCT01536067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01856933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: 2.5 mg/kg, IV, over 60 minutes every 3 weeks
Study NCT03047252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation with a digital biofeedback system
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises
Study NCT03047252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Home-based rehabilitation
Description: Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application
Study NCT02593240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food
Description: The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
Study NCT02593240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher
Description: The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
Study NCT02593240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Performance Institute©
Description: The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
Study NCT01582347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6300
Description: Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate.
Study NCT01582347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex®/Suboxone®
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.
Study NCT01054534 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placement of interstim lead
Description: Placement of insterstim lead using US image fusion technology
Study NCT04228744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS system
Description: The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation.